The Centers for Medicare & Medicaid services (CMS) proposes to change the method of reimbursement for outpatient hemodialysis such that a fixed payment bundle will cover both outpatient dialysis therapy and injectable medications. The proposal does not include an adjustment for race, although this is up for debate. We aimed to determine if African Americans, compared with whites, continue to initiate dialysis with lower hemoglobin concentrations and require higher doses of erythropoiesis stimulating agents (ESA) to achieve similar hemoglobin concentrations, as they have historically. We constructed a cohort of 12,002 ESA-naive patients older than 67 yr who initiated hemodialysis between January 1, 2006 and October 31, 2006, had Medicare as their primary payer for 2 yr preinitiation, and received erythropoietin (EPO) during the first 2 mo postinitiation. At dialysis initiation, African Americans had lower hemoglobin values than whites (9.9 Ϯ 1.7 versus 10.3 Ϯ 1.6 g/dl, P Ͻ 0.001). On average, after adjusting for multiple variables (but not initial hemoglobin concentration), African Americans required 11.0% more EPO than whites (P Ͻ 0.001). With initial hemoglobin included in the model, this difference was attenuated to 6.8% more EPO than whites (P Ͻ 0.001). In conclusion, if CMS implements its proposed reimbursement scheme, facilities may have a financial disincentive to treat African Americans, potentially resulting in reduced access to outpatient dialysis therapy.
The Centers for Medicare & Medicaid services (CMS) has proposed to change the method by which outpatient hemodialysis is reimbursed. Under the current schema, outpatient dialysis is billed at a fixed rate, and intravenous (IV) medications are billed separately on the basis of dose. In the current system, greater use and higher doses of IV medications result in increased revenue for outpatient dialysis facilities, potentially creating an incentive toward greater use of outpatient IV medications. Under the proposed new payment scheme, a fixed payment bundle will cover outpatient dialysis therapy and injectable medications. 1 The proposal attempts to adjust for cost differences between patients by using basic case-mix information to modify the monthly capitated dialysis payment. Proposed adjusters to the base payment include age, body mass index (BMI), body surface area, and locality. The proposal as recommended by CMS does not adjust for race, but this point is currently up for debate. 2 Historically, African Americans have initiated dialysis with lower hemoglobin concentrations than whites and are less likely to have received erythropoiesis stimulating agent (ESA) therapy before initiating dialysis. 3 However, for given hemoglobin concentrations, outcomes for African Amer-icans appear similar to outcomes for whites. 4 Furthermore, African Americans may require higher ESA doses than whites to achieve similar hemoglobin concentrations for reasons such as intrinsic resistance, poorer dialysis, or higher weight. 5 A fixed-rate reimbursement system with no adjustment for race or separate billing for medications may bias against African Americans, because they may require higher ESA doses to achieve National Kidney Foundation Kidney Disease Outcomes Quality Initiative 6 recommended hemoglobin targets. We thus aimed to determine in a modern cohort if (1) African Americans continue to initiate hemodialysis with lower hemoglobin concentrations than whites, and (2) African Americans use higher ESA doses than whites after hemodialysis initiation.
RESULTS
Between January 1, 2006 and October 31, 2006, 40,942 patients aged older than 67 yr initiated hemodialysis. We excluded those without Medicare as primary insurance type (n ϭ 12,676) and those who had used ESAs during the 2 yr preinitiation (n ϭ 9558). Of the remaining 18,708, 4602 had no ESA claims in the first 2 calendar months after initiating dialysis and were excluded. An additional 2041 were excluded because at least one of the following variables was missing from the Medical Evidence Report: hemoglobin, BMI, creatinine, or access type. Finally, because of the skewed distribution of erythropoietin (EPO) dose in the first 2 mo, we trimmed the extreme 0.25% of patients on both sides of the mean. This left 12,002 individuals in our final analysis cohort (Figure 1 ).
Participants included in our final cohort (n ϭ 12,002) were generally similar to those excluded (n ϭ 28,940) with the following exceptions: in logistic regression analysis, included participants were more likely to be older [odds ratio (OR) 1 
Initial Hemoglobin
At dialysis initiation, African Americans had lower hemoglobin values than whites (9.9 Ϯ 1.7 versus 10.3 Ϯ 1.6 g/dl, P Ͻ 0.001). However, more African Americans than whites in our cohort were women (58.9 versus 44.1%), a possible influence on the initial hemoglobin concentration. In multiple variable regression analysis, including adjustment for sex, a small difference (Ϫ0.348 g/dl, P Ͻ 0.001) remained in initial hemoglobin concentrations between African Americans and whites (Table 3) .
EPO Dose
Average EPO dose after dialysis initiation was an age-adjusted 94,222 units per month. Race significantly influenced the EPO dose. On average, after adjusting for age, whites used 93,132 units of EPO and African Americans 100,659 units. In multivariable regression analysis (Table 4) , with EPO dose logtransformed, and not including the initial hemoglobin concentration, African Americans continued to require significantly higher EPO units. On average, African Americans required 11.0% (P Ͻ 0.001) more EPO than whites. These results were attenuated when initial hemoglobin concentration was added to the model, but still showed African Americans using 6.8% (P Ͻ 0.001) more EPO units per month than whites. CLINICAL EPIDEMIOLOGY www.jasn.org
Stratified Analysis
Vascular access at dialysis initiation was a significant predictor of hospitalization during the first 2 mo of dialysis. Percents of patients hospitalized during the first 2 mo by vascular access type were: arteriovenous (AV) fistula, 29.2%; graft, 39.7%; catheter, 42.2% (P Ͻ 0.001). When stratified by initial vascular access type, African Americans continued to require higher doses of EPO, irrespective of vascular access type (AV fistula 7.1% more, P ϭ 0.2; graft 14.0% more, P ϭ 0.06; catheter 6.6% more, P Ͻ 0.001; table not shown.)
DISCUSSION
Our results in a cohort of older hemodialysis patients incident in 2006 demonstrate that despite similar health insurance and BMI, African Americans initiate hemodialysis with lower hemoglobin concentrations than whites. Additionally, in multivariable analysis, African Americans require approximately 11.0% more EPO units per month than whites per month for the first 2 mo after initiating dialysis. We chose not to include hemoglobin in our primary model, because we were interested in determining actual EPO use from a payer perspective. However, even when accounting for initial hemoglobin concentrations, African Americans still require 6.8% more EPO units per month than whites. This difference in EPO use may have policy implications, given the upcoming changes in dialysis reimbursement by Medicare. Our observation of lower hemoglobin concentrations among African Americans than whites is similar to earlier observations. 7, 8 Ward et al., 9 using a cohort of dialysis patients incident between 1996 and 2004, demonstrated that hemoglobin concentration at dialysis initiation was lower for African Americans than whites, and that African Americans were less likely to have been treated with ESAs before dialysis initiation. Part of this discrepancy was related to the absence of medical insurance at dialysis initiation. Similar results have been observed using prevalent dialysis cohorts. 10 Frankenfield et al., 11 using the ESRD core indicator project (a random sample of prevalent dialysis patients), indicated that despite similar body surface area values, African Americans required higher total EPO doses than whites after adjusting for weight. Specifically, African Americans used approximately 2400 more EPO units CLINICAL EPIDEMIOLOGY www.jasn.org per month than whites. Despite higher doses, hematocrit values for African Americans remained lower than for whites (33.0 versus 33.2%). Also, African Americans were more likely to have hematocrit values below target (Ͻ28%) than whites (12 versus 9%).
Not all previous studies support these observations. Coladonato et al. 12 also used the ESRD core indicator project and observed a similar difference in hematocrit between African Americans and whites (32.2 versus 32.6%), but no difference in EPO dose, after adjustment for predialysis weight. However, predialysis weights in their cohort were significantly higher for African Americans than whites, 11 suggesting that total EPO use may have been higher among African Americans. Finally, Lacson et al. 13 recently examined EPO dose differences by race in a prevalent hemodialysis cohort in the Fresenius Medical Care system. In unadjusted analysis, African Americans used approximately 12.6% more EPO than whites; however, this difference in EPO dose disappeared in multivariable analysis. The primary factors responsible for the difference in EPO dose were Kt/V, parathyroid hormone, and white blood cell count. Although differences in these factors may explain the "causal" difference in EPO dose between African Americans and whites, none of the factors are included in the new Medicare dialysis reimbursement proposal. Thus, the newly proposed dialysis bundle may provide reimbursement for African Americans that is disproportionately low compared with white dialysis patients.
Overall, these results, combined with our own, suggest that African Americans initiate dialysis with lower hemoglobin concentrations than whites, and that the difference persisted into 2006. We also observed a difference in initial hemoglobin concentrations between African Americans and whites, despite similar medical insurance types in the 2 yr before dialysis initiation. Additionally, African Americans appear to require higher ESA doses. In our cohort, despite adjusting for BMI and other factors considered in the new dialysis reimbursement bundle, African Americans used approximately 11.0% more EPO than whites, and this difference persisted after adjustment for initial hemoglobin concentration.
Numerous factors could account for the difference in hemoglobin values and ESA doses between African Americans and whites. First, in the general population, healthy African Americans have lower hemoglobin concentrations than whites, possibly reflecting an increased frequency of an alpha thalassemia deletion allele. 14 African Americans on dialysis are generally younger and tend to miss more dialysis sessions than whites, potentially affecting Kt/V, parathyroid hormone, 13 and overall anemia management. 15 African Americans tend to have poorer dialysis than whites, also affecting anemia management. 16 Finally, in a post hoc analysis of the POWER trial, 17 African American nonsmokers had a diminished erythropoietic response compared with nonsmokers of other races, leading to lower hemoglobin concentrations despite controlling for ESA dose. Overall, these factors support our observation that African Americans require higher ESA doses than whites to achieve similar hemoglobin concentrations.
Although African Americans initiate hemodialysis with lower hemoglobin concentrations and require higher EPO doses during the first 2 mo of dialysis, their outcomes appear to be the same as outcomes for whites. In an incident hemodialysis population, there was no difference in time to first hospitalization between African Americans and whites in an analysis stratified by initial hemoglobin concentration. 4 However, interpreting these observational results is difficult given the recent clinical trial evidence regarding ESA use and outcomes. 18 -20 Most dialysis facilities in the United States are for-profit entities. Currently, outpatient dialysis facilities generate revenue principally by two means: they bill for outpatient dialysis services and they bill for administration of IV medications. Given that the current reimbursement policy is tied to dose of medication administered, facilities have incentives to aggressively treat anemia using profitable, separately billable drugs such as EPO. 1 The reimbursement change that CMS recently proposed to Congress, using a fixed base payment to cover the outpatient dialysis procedure and any injectable medications used during dialysis, would be "fully prospective in that facilities would ). In determining how outpatient dialysis reimbursement should be changed, CMS did not consider race. If African Americans require higher ESA doses to achieve and maintain target hemoglobin concentrations, and they initiate dialysis with lower hemoglobin concentrations (also not accounted for in the reimbursement model), costs of providing dialysis care could be higher than reimbursement rates, possibly creating a disincentive to treat Africans Americans, and thus difficulties gaining access to care.
Our study is limited in several ways. Our cohort consisted of a very select population, specifically, patients aged older than 67 yr at dialysis initiation with Medicare as the primary insurance provider. As a result of our inclusion/exclusion criteria, patients included in our final cohort were likely very different from the general pool of patients aged older than 67 yr initiating dialysis. Given this difference, it is unclear how generalizable our results are to the overall hemodialysis population. However, our results are similar to previous observations in incident and prevalent dialysis populations. Also, our cohort consisted of incident hemodialysis patients in 2006. Since this time, several studies 18 -20 have suggested that increased hemoglobin concentrations may be associated with adverse health effects. These studies have resulted in numerous changes in anemia management, including changes in the labeled indication for ESAs, changes in reimbursement for ESA therapy, and changes in the target hemoglobin for dialysis patients. How all of these changes have influenced prescribing ESAs to hemodialysis patients is unclear. Although the changes may influence ESA doses over time, they likely do not influence initial ESA dosing, which is typically based on baseline hemoglobin and body weight.
Our results suggest that patients using catheters for dialysis access required fewer units of EPO than those using AV fistulas or grafts. This observation is in contrast to previous studies and is likely the result of our method of calculating EPO dose. We could determine only EPO doses adminis- CLINICAL EPIDEMIOLOGY www.jasn.org tered in the outpatient setting. Patients with catheters were more likely to have been hospitalized during the initial 2 mo of dialysis and more likely to have been administered EPO during their inpatient stays, doses for which we could not account. We attempted to adjust for this by calculating EPO dose per outpatient day at risk. Additionally, our results did not change when we stratified by form of vascular access at baseline.
Overall, African American patients initiate hemodialysis with lower hemoglobin concentrations than whites. Additionally, African Americans require approximately 11.0% more EPO during the first few months of dialysis than whites. If this trend toward higher EPO use continues throughout the time on dialysis, and if CMS implements its currently proposed reimbursement scheme, African Americans may experience reduced access to outpatient dialysis therapy, because facilities may have a financial disincentive to accept African American patients.
CONCISE METHODS
We constructed a cohort of ESA-naïve patients who initiated hemodialysis between January 1, 2006 and October 31, 2006. Participants were required to be aged older than 67 yr at dialysis initiation and to have had Medicare as their primary source of insurance during the 2 yr before dialysis initiation. To ensure no prior ESA use at dialysis initiation, patients with Healthcare Common Procedure Coding System codes Q0136, Q0137, J0880, Q4054, and Q4055; revenue codes 0634 and 0635; and value code 68 present in their Medicare claims during the 2 yr before dialysis initiation were excluded from cohort entry. ESA therapy during the first 2 calendar months after hemodialysis initiation was also a required condition of cohort entry.
Predictor Variable: EPO Dose
Outpatient EPO use was determined from Medicare claims submitted by outpatient dialysis facilities in the first 2 calendar months after dialysis initiation. We did not include darbepoetin doses in our analysis because it was prescribed for only seven patients in our cohort during the initial 2 mo of hemodialysis. EPO doses administered during inpatient hospital stays are not billed separately to Medicare and thus could not be determined. Consequently, total outpatient EPO dose may underestimate total EPO dose used. To account for this bias, the number of days in hospital was determined for each patient on the basis of Medicare claims. Mean monthly EPO dose per outpatient day at risk was calculated for each patient by summing the total dose equivalent over a calendar month, dividing by the number of outpatient days at risk, and multiplying by 30 to obtain the total EPO dose in a calendar month (30 d).
Baseline Characteristics
Baseline characteristics at dialysis initiation were determined from the CMS ESRD Medical Evidence Report (form CMS-2728). Data extracted included demographics (age, race, sex), height, weight, comorbid conditions, primary cause of ESRD, laboratory data (hemoglobin, creatinine), and type of vascular access. BMI was determined for all patients using the Dubois formula [weight (kg)/height (m 2 )].
Statistics
Baseline characteristics were compared using t test for continuous variables and 2 tests for categorical variables. Linear regression was conducted to determine correlates of hemoglobin at dialysis initiation. Factors included in the regression model included, age, race, sex, BMI, comorbid conditions as reported on the Medical Evidence Report, vascular access type, and estimated GFR at dialysis initiation.
To determine the association between race and EPO dose during the first 2 calendar months after dialysis initiation, we constructed a linear regression model with monthly EPO dose as the predictor variable. Because it was highly skewed, monthly EPO dose was log-transformed, and the extreme was 0.25% trimmed. The skewness and kurtosis of monthly EPO dose before being log-transformed and trimmed were 1.48 and 5.21, respectively, and became Ϫ1.05 and 1.67 after transformation and trimming. As a result of this transformation, when interpreting the linear regression model, the parameter estimate for race reflects the percent difference in EPO dose between races (e.g., the percent difference in EPO dose for African Americans is calculated by the exponent of the coefficient of African Americans minus 1). Factors included in this linear regression model are age, race, sex, BMI, vascular access type, comorbid conditions, and estimated GFR. Initial hemoglobin was not included in our main model because our primary intent was to determine differences in EPO doses between races. We constructed a secondary analysis including initial hemoglobin. Also, because information on EPO units administered during inpatient hospitalizations is unavailable, we conducted a stratified analysis by type of vascular access at dialysis initiation (reported on the Medical Evidence Report), because vascular access significantly influenced the number and duration of hospitalizations during the first 2 calendar months after initiation.
For all analyses, we considered outcomes to be statistically significant if the two-sided P value was Ͻ0.05. All analyses were conducted using SAS 9.1 (Cary, NC).
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